Skip to main content
. Author manuscript; available in PMC: 2020 Oct 6.
Published in final edited form as: Gynecol Oncol. 2019 Aug 16;155(1):39–50. doi: 10.1016/j.ygyno.2019.08.007

Fig. 3.

Fig. 3.

Composite endpoint, ovarian adverse event, and sensitivity analysis. Composite endpoint (recurrence, death, or metachronous secondary malignancy) for (A) the US cohort and (B) the Japan cohort is shown per adnexal surgery type (ovarian conservation versus oophorectomy). (C) Overall survival and (D) cumulative risk of ovarian adnexal event (ovarian recurrence or metachronous secondary ovarian cancer) are shown based on the study cohort. Disease-free survival is shown comparing ovarian conservation and ERT for (E) the US cohort and (F) the Japan cohort. Abbreviations: OC, ovarian conservation; and ERT, estrogen replacement therapy.